Conversely, AR can bind to the NXTAR promoter and inhibit AR expression using a small molecule inhibitor of ACK1/TNK2, thereby inhibiting the proliferation of enzalutamide-resistant cells and reducing enzalutamide resistance during tumor therapy. Here, AR is linked to neoplasm.